Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.50 |
| ▸ | PPARG | P37231 | 7/20 | 0.50 |
| ▸ | PPARD | Q03181 | 7/20 | 0.50 |
| ▸ | PPARA | Q07869 | 7/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | FABP4 | P15090 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31202391 | 1.00 | LTA4H (0.62) | LTA4HTSHRLMNANFKB1PMP22 | |
| SCHEMBL21067349 | 1.00 | LTA4H (0.62) | LTA4HTSHRLMNANFKB1PMP22 | |
| Alanine SCHEMBL15656769 | 0.86 | TSHR (0.60) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| Alanine SCHEMBL28198684 | 0.86 | TSHR (0.60) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| Sebacic Acid SCHEMBL15655096 | 0.86 | TSHR (0.60) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| Azelaic Acid SCHEMBL29465682 | 0.85 | TSHR (0.67) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| Adipic Acid SCHEMBL15657486 | 0.83 | LMNA (0.58) | LTA4HTSHRLMNANFKB1PMP22 | |
| SCHEMBL1834739 | 0.83 | TSHR (0.63) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| Adipic Acid SCHEMBL15657487 | 0.83 | LMNA (0.58) | LTA4HTSHRLMNANFKB1PMP22 | |
| SCHEMBL1986431 | 0.83 | GABRP (0.54) | LTA4HTSHRLMNANFKB1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658805-A1 | METHODS FOR IDENTIFYING HERBICIDAL COMPOUNDS | Syngenta Crop Protection AG (CH) | 2025-12-10 | — | — | EP | claimed |
| US-20240368659-A1 | MICROBIAL CELL FACTORIES PRODUCING VITAMIN B COMPOUNDS | BIOSYNTIA APS (DK) | 2024-11-07 | — | — | US | claimed |
| CN-118792227-A | Method for improving acarbose yield | 上海医药工业研究院有限公司 | 2024-10-18 | — | — | CN | claimed |
| WO-2024160975-A1 | METHODS FOR IDENTIFYING HERBICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2024-08-08 | — | — | WO | claimed |
| EP-4370653-A2 | MICROBIAL CELL FACTORIES PRODUCING VITAMIN B COMPOUNDS | Biosyntia ApS (DK) | 2024-05-22 | — | — | EP | claimed |
| US-11851461-B2 | Cell factory having improved iron-sulfur cluster delivery | BIOSYNTIA APS (DK) | 2023-12-26 | — | — | US | claimed |
| CN-117143789-A | Construction and application of corynebacterium glutamicum for producing ectoin by one-step method | 森瑞斯生物科技(深圳)有限公司 | 2023-12-01 | — | — | CN | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-115197887-B | Full-biological synthesis method for producing pimelic acid by utilizing Kleisen condensation reaction | 江南大学 | 2023-08-25 | — | — | CN | claimed |
| US-20230192778-A1 | CELL FACTORY HAVING IMPROVED IRON-SULFUR CLUSTER DELIVERY | BIOSYNTIA APS (DK) | 2023-06-22 | — | — | US | claimed |
| EP-2632903-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2013-09-04 | — | — | EP | claimed |
| WO-2012058529-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | WO | claimed |
| WO-2012058686-A2 | HYBRID POLYKETIDE SYNTHASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-03 | — | — | WO | claimed |
| WO-2011067553-A1 | CELLS FOR THE PRODUCTION OF BIOTIN - TAGGED VIRAL VECTORS OR PROTEINS | KING'S COLLEGE LONDON (GB) | 2011-06-09 | — | — | WO | claimed |
| US-20100210569-A1 | Mitochondria-targeting antioxidant therapeutics | STELIOU KOSTA | 2010-08-19 | — | — | US | claimed |
| EP-1577394-B1 | DNA fragment containing biotin biosynthesis gene and utilization thereof | SUMITOMO CHEMICAL CO (JP) | 2009-07-15 | — | — | EP | claimed |
| EP-0913475-B1 | DNA FRAGMENTS CONTAINING BIOTIN BIOSYNTHETASE GENE AND USE OF THE SAME | SUMITOMO CHEMICAL CO (JP) | 2009-06-03 | — | — | EP | claimed |
| WO-2009038656-A1 | MITOCHONDRIA-TARGETING ANTIOXIDANT THERAPEUTICS | STELIOU KOSTA (US) | 2009-03-26 | — | — | WO | claimed |
| US-20040006040-A1 | Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway and compounds and pharmaceutical compositions useful therefor | PYRO PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | claimed |
| EP-0892066-B1 | Overcoming DAPA aminotransferase bottlenecks in biotin vitamers | HOFFMANN LA ROCHE (CH) | 2003-04-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006040-A1 | Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway and compounds and pharmaceutical compositions useful therefor | CYP51A1, ME1, BPGM | LTA4H 497/4885TSHR 4468/4885LMNA 3872/4885 |
| US-20100210569-A1 | Mitochondria-targeting antioxidant therapeutics | SLC25A20, TXNRD2, TXN2 | LTA4H 1863/4885TSHR 4234/4885LMNA 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.